Science Explorer Interactive view Map

Histone Deacetylase Inhibitors Research

Histone Deacetylase Inhibitors Research is a research topic within Molecular Biology. Science Explorer counts 21k research works in it since 1953. 22.5% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the role of histone deacetylases (HDACs) in regulating cellular functions, gene expression, and epigenetic modifications. It covers the use of HDAC inhibitors in cancer therapy, their impact on neurodegenerative disorders, and their involvement in protein complexes and enzymatic activity.

  • Histone Deacetylases
  • HDAC Inhibitors
  • Epigenetic Regulation
  • Cancer Therapy
  • Cellular Functions
  • Acetylation
  • Gene Expression
  • Neurodegenerative Disorders
  • Protein Complexes
  • Enzymatic Activity
Research works
21k
fractional, since 1953
In the world top 10%
4.8k
per year above
Top-10% rate
22.5%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+15%
the tick is no change

Which countries lead Histone Deacetylase Inhibitors Research research?

By volume, China and the United States publish the most (1.5k and 1.1k works in 2022–2025).

By volume, 2022–2025

  1. 1 China 1.5k works
  2. 2 United States 1.1k works
  3. 3 India 242 works
  4. 4 Germany 176 works
  5. 5 Italy 161 works
  6. 6 Japan 139 works
  7. 7 South Korea 136 works
  8. 8 United Kingdom 102 works
  9. 9 France 76 works
  10. 10 Canada 74 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 41.3%United States: 28.7%India: 6.6%Germany: 4.8%6 others listed: 18.7%41%largest
China1,522 · 41.3%United States1,057 · 28.7%India242 · 6.6%Germany176 · 4.8%6 others listed688 · 18.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Histone Deacetylase Inhibitors Research research?

By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Histone Deacetylase Inhibitors Research research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sichuan University.

Who are the leading researchers in Histone Deacetylase Inhibitors Research?

The most-cited researchers publishing on Histone Deacetylase Inhibitors Research include Hagop M. Kantarjian and Gordon B. Mills.

  1. 1 Hagop M. Kantarjian United States 4k citations
  2. 2 Gordon B. Mills United States 3.7k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Histone Deacetylase Inhibitors Research research done?

The largest centres of Histone Deacetylase Inhibitors Research research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Houston.

Largest cities, 2022–2025

  1. 1 Beijing China 146 works
  2. 2 Shanghai China 116 works
  3. 3 Guangzhou China 99 works
  4. 4 Nanjing China 77 works
  5. 5 Hangzhou China 69 works
  6. 6 Houston United States 69 works
  7. 7 Chengdu China 61 works
  8. 8 Seoul South Korea 60 works
  9. 9 Wuhan China 55 works
  10. 10 New York United States 53 works

Where it is the local speciality

  1. HoustonUS · 69.0 works6.3×
← less than its size predictsmore →

Location quotient: how much more of its research is in Histone Deacetylase Inhibitors Research than the world average.

See Histone Deacetylase Inhibitors Research on the map

Where is the best place to study Histone Deacetylase Inhibitors Research?

Among universities, judged by research, China Medical University, China Pharmaceutical University and Sichuan University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 33.3%fractional works in this node (log) →share in the world top 10% →China Medical University: 19, 41.2%China Pharmaceutical University: 20, 37.8%Sichuan University: 26, 33.5%Shandong First Medical University: 9, 41.2%Zhengzhou University: 16, 33.3%Chinese Academy of Medical Sciences & Peking Union Medical College: 28, 28.6%University of Bonn: 8, 41.5%Sun Yat-sen University: 23, 30.4%Nanjing University of Chinese Medicine: 11, 23.4%Shenyang Pharmaceutical University: 11, 22.1%China Medical Univer…Shandong First Medic…China Pharmaceutical…Sichuan University
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 China Medical UniversityChina 70.741.2%13.3×19 +58.6%
2 China Pharmaceutical UniversityChina 69.437.8%21.7×20 +75.0%
3 Sichuan UniversityChina 59.033.5%3.5×26 +239.5%
4 Shandong First Medical UniversityChina 58.141.2%8.1×9
5 Zhengzhou UniversityChina 56.333.3%4.3×16 +296.0%
6 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 55.328.6%6.6×28 +63.2%
7 University of BonnGermany 51.541.5%5.4×8 -12.8%
8 Sun Yat-sen UniversityChina 48.630.4%3.3×23 +97.9%
9 Nanjing University of Chinese MedicineChina 47.223.4%10.3×11
10 Shenyang Pharmaceutical UniversityChina 45.722.1%19.4×11

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Histone Deacetylase Inhibitors Research research growing?

Output in 2018–2022 was 15% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Histone Deacetylase Inhibitors Research.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.